zidovudine has been researched along with HIV-Associated Lipodystrophy Syndrome in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 35 (81.40) | 29.6817 |
| 2010's | 7 (16.28) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Begovac, J; Šoštarić Zadro, A; Višković, K | 1 |
| Fekade, D; Feleke, Y; Mezegebu, Y | 1 |
| Guo, F; Li, T; Lin, Q; Shao, H; Sun, P; Tian, J; Xu, Y; Yu, W; Zhou, X | 1 |
| Atté, EF; Rasschaert, F; Reid, T; van Griensven, J; Zachariah, R | 1 |
| Portilla, J | 1 |
| Casoli, V; Délia, G; Martin, D; Rousvoal, A | 1 |
| Berzins, B; Evans, S; Forand, J; Hafner, R; Murphy, R; Owens, S; Shevitz, A; Tashima, K; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Benn, P; Cartledge, J; Edwards, SG; Linney, A; Moyle, G; Reilly, G; Ruff, C; Sabin, CA; Sauret-Jackson, V | 1 |
| Eriksson, P; Setzer, B; Sevastianova, K; Sievers, M; Sutinen, J; Wågsäter, D; Walker, UA; Yki-Järvinen, H | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Arribas López, JR | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Boué, F; Briot, K; Cohen-Codar, I; Delfraissy, JF; Flandre, P; Knysz, B; Kolta, S; Morlat, P; Norton, M; Pintado, C; Rode, R; Roux, C; Valantin, MA; Van, PN | 1 |
| Conway, K; Peters, BS | 1 |
| Gu, WB; Han, Y; Li, TS; Li, YL; Qiu, ZF; Wu, P; Xie, J; Zhang, L | 1 |
| Capeau, J; Danner, SA; Domingo, P; Feeney, ER; Mallon, PW; Reiss, P; van Agtmael, MA; van Vonderen, MG; Villarroya, F; Wit, F | 1 |
| Lauenroth-Mai, E; Schlote, F | 1 |
| Aboulker, JP; Flandre, P; Harel, M; Joly, V; Leturque, N; Meiffredy, V; Yeni, P | 1 |
| Carr, A; Cooper, DA; Hoy, J; Hudson, J; Law, M; Martin, A; Smith, DE | 1 |
| Oka, S; Teruya, K | 1 |
| Herrmann, SE; James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB; Nolan, DA; White, AJ | 1 |
| Domingo, P; Ordoñez, J; Pérez, A; Rodriguez, J; Sambeat, MA; Vázquez, G | 1 |
| Maa, JF; McComsey, G | 1 |
| Amin, J; Carr, A; Cooper, DA; Doong, N; Emery, S; Freund, J; Hoy, J; Martin, A; Ringland, C; Smith, DE; Workman, C | 1 |
| Brinkman, K; Casula, M; de Ronde, A; Hulsebosch, HJ; Lange, J; Nieuwkerk, P; Reiss, P; van der Valk, M; van Eck-Smit, B; van Eeden, A; van Kuijk, K; Weverlingz, GJ | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
| Cherry, CL; Fisher, RL; Hernandez, JE; Hessenthaler, SM; Hoppel, CL; Lonergan, JT; McComsey, GA; Paulsen, DM; Ross, LL; Ross, ST; Thompson, KA; White-Owen, C; Williams, VC | 1 |
| Cherry, CL; Hernandez, J; Lal, L; McComsey, G; McLean, CA; Ross, LL; Thompson, KA; Wesselingh, SL | 1 |
| Beauvoit, B; Breilh, D; Carrière, A; Caspar-Bauguil, S; Casteilla, L; Deveaud, C; Fernandez, Y; Galinier, A; Gordien, JB; Hagry, S; Penicaud, L; Rigoulet, M; Salin, B; Schaeffer, J | 1 |
| Giacomet, V; Viganò, A | 1 |
| Back, DJ; Gazzard, BG; Jones, SP; Lebrecht, D; Morelese, J; Moyle, GJ; Pirmohamed, M; Qazi, N; Sutinen, J; Walker, UA; Yki-Jărvinen, H | 1 |
| Moyle, GJ | 1 |
| Nolan, D | 1 |
| Arathoon, E; Arlotti, M; Giordano, M; Jemsek, JG; Noor, MA; Perez, C; Pokrovskiy, V; Soccodato, M; Sosa, N; Thiry, A | 1 |
| Cartledge, J; Churchill, D; Fakoya, A; Hay, P; Johnson, M; Leen, C; Moyle, GJ; Murphy, M; Reilly, G; Sabin, CA; Scullard, G; Wilkins, E | 1 |
| Amellal, B; Calvez, V; Castro, ND; Chêne, G; Cotte, L; Gourlain, K; Journot, V; Molina, JM; Palmer, P; Pédrono, G; Rancinan, C | 1 |
| Behrens, GM; Das, AM; Lücke, T; Schmidt, RE; Stankov, MV | 1 |
| Nelson, M; Waters, L | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Ackermans, M; Blümer, RM; Danner, SA; Hassink, E; Reiss, P; Sauerwein, HP; Sutinen, J; van Agtmael, MA; van Vonderen, MG; Yki-Jarvinen, H | 1 |
| Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mougnutou, R; Mpoudi-Ngolé, E; Nkoué, N | 1 |
8 review(s) available for zidovudine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Glucose Metabolism Disorders; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Multicenter Studies as Topic; Organophosphonates; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zidovudine | 2008 |
[Adipose tissue hypertrophy after Lipostructure in HIV patient with antiretroviral treatment. Case report and literature review].
Topics: Adipose Tissue; Adult; Anti-Retroviral Agents; Drug Combinations; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypertrophy; Lamivudine; Male; Postoperative Complications; Zidovudine | 2009 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
Therapy for HIV: past, present, and future.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Zidovudine | 2011 |
[Antiretrovirals].
Topics: Acidosis, Lactic; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children.
Topics: Acidosis, Lactic; Anti-HIV Agents; Cardiomyopathies; Child; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Mitochondria; Nucleosides; Polyneuropathies; Reverse Transcriptase Inhibitors; Zidovudine | 2005 |
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Metabolic Syndrome; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zidovudine | 2005 |
Long-term complications of antiretroviral therapy: lipoatrophy.
Topics: Anti-HIV Agents; Body Image; Cardiovascular Diseases; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Stavudine; Time Factors; Zidovudine | 2007 |
18 trial(s) available for zidovudine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Intra-Abdominal Fat; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Radiography, Abdominal; Stavudine; Thigh; Viral Load; Zidovudine | 2009 |
Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Body Composition; Cheek; Dideoxynucleosides; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Body Fat Distribution; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Atrophy; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Subcutaneous Fat; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Constitution; Body Mass Index; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Lamivudine; Male; Middle Aged; Risk Factors; Stavudine; Zidovudine | 2002 |
Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study.
Topics: Anti-HIV Agents; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Stavudine; Substance Withdrawal Syndrome; Thymidine; Zidovudine | 2002 |
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
Topics: Adult; Body Composition; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Stavudine; Zidovudine | 2003 |
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Topics: Absorptiometry, Photon; Adipose Tissue; Anti-HIV Agents; Body Composition; Bone Density; Dideoxynucleosides; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; DNA, Mitochondrial; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Leukocytes, Mononuclear; Middle Aged; Muscle, Skeletal; Radiography; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Topics: Adiposity; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Oligopeptides; Oxazines; Pyridines; Zidovudine | 2006 |
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Fat Distribution; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2006 |
Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.
Topics: Adult; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Leukocytes, Mononuclear; Logistic Models; Male; Reverse Transcriptase Inhibitors; Stavudine; Surveys and Questionnaires; Time Factors; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Topics: Adiponectin; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Glucose; Glycerol; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Insulin Resistance; Lamivudine; Lipid Metabolism; Lipids; Lopinavir; Male; Middle Aged; Pyrimidinones; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Multivariate Analysis; Nevirapine; Patient Compliance; Peripheral Nervous System Diseases; Prospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
17 other study(ies) available for zidovudine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
REVERSIBILITY OF LIPOATROPHY IN HIV-INFECTED PATIENTS TAKING ANTIRETROVIRAL THERAPY: A COHORT STUDY WITH ULTRASOUND ASSESSMENT.
Topics: Cohort Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Longitudinal Studies; Prospective Studies; Stavudine; Zidovudine | 2022 |
Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Topics: Adult; Aged, 80 and over; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Ethiopia; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Interviews as Topic; Male; Metabolic Diseases; Middle Aged; Prevalence; Risk Factors; Stavudine; Surveys and Questionnaires; Zidovudine | 2012 |
[To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].
Topics: Absorptiometry, Photon; Adenine; Anti-HIV Agents; Antiviral Agents; Body Composition; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2014 |
Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Organophosphonates; Rwanda; Stavudine; Tenofovir; Treatment Outcome; Weight Loss; Zidovudine | 2009 |
Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
Topics: Adipocytes; Anti-HIV Agents; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Female; Gene Expression Profiling; Gene Expression Regulation, Viral; Glucose; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Immunohistochemistry; Lipid Metabolism; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Subcutaneous Fat, Abdominal; Zidovudine | 2009 |
[Association between the change regularity of peripheral blood mononuclear cell mitochondrial deoxyribonucleic acid content and human immunodeficiency virus-related lipodystrophy].
Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; DNA, Mitochondrial; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Stavudine; Young Adult; Zidovudine | 2011 |
HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy.
Topics: Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort Studies; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Time Factors; Zidovudine | 2002 |
Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
Topics: Adult; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Exercise; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Integration Host Factors; Leptin; Male; Middle Aged; Retrospective Studies; Stavudine; Zidovudine | 2003 |
[Long-term tolerance. Preventing lipoatrophy].
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Long-Term Care; Risk Factors; Stavudine; Zidovudine | 2003 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
Topics: Adipocytes; Adipose Tissue; Adult; Apoptosis; Dideoxynucleosides; DNA, Mitochondrial; Electron Transport; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Muscle, Skeletal; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2005 |
Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.
Topics: Adipocytes; Adipose Tissue; Adult; Anti-HIV Agents; Apoptosis; Biopsy; Dideoxynucleosides; DNA; DNA Fragmentation; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; In Situ Nick-End Labeling; Male; Middle Aged; Stavudine; Zidovudine | 2005 |
Site specific alterations of adipose tissue mitochondria in 3'-azido-3'-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy?
Topics: Adipose Tissue; Animals; Anti-HIV Agents; DNA, Mitochondrial; Electron Transport Complex IV; HIV-Associated Lipodystrophy Syndrome; Liver; Male; Mitochondria; Oxidation-Reduction; Oxidative Stress; Pyruvic Acid; Rats; Rats, Wistar; Weight Gain; Zidovudine | 2005 |
Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
Topics: Adiponectin; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Mitochondrial; Drug Therapy, Combination; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Interleukin-6; Male; Middle Aged; Mitochondria; Reverse Transcriptase Inhibitors; Stavudine; Sterol Regulatory Element Binding Protein 1; Tumor Necrosis Factor-alpha; Zidovudine | 2005 |
The role of zidovudine in development of lipoatrophy.
Topics: Adipose Tissue; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Mice; Randomized Controlled Trials as Topic; Rats; Reverse Transcriptase Inhibitors; Zidovudine | 2005 |
Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cell Differentiation; Cell Proliferation; Cell Shape; Dideoxynucleosides; DNA, Mitochondrial; Dose-Response Relationship, Drug; Electron Transport; HIV-Associated Lipodystrophy Syndrome; Mice; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Triglycerides; Zalcitabine; Zidovudine | 2007 |